LONDON (Alliance News) - IXICO PLC said Monday it signed an expansion to an existing trial study contract with an unnamed pharmaceutical company, worth GBP600,000.
The additional services to be provided by the company increased the value of the three-year contract to GBP1.6 million, IXICO said.
The original contract was signed in mid-May, when IXICO explained that, under the agreement, it would provide its technology-enabled imaging services in a study of people with early manifest Huntington's disease to observe the natural progression of the disease.
"I am delighted that our client has decided to expand our involvement at such an early stage of this important study," Chief Executive Officer Giulio Cerroni said.
"We value the strength of our relationships with pharmaceutical companies and our ability to provide them with important insights to support their efforts to bring new medicines to market," he added.
IXICO shares were untraded at 30.01 pence each on Monday.
Ixico (IXI)